Name | Relative Retention Time | Limit (%) |
Cabergoline related compound D1 | 0.3 | NMT 0.1 |
Cabergoline related compound B2 | 0.6 | NMT 0.1 |
Cabergoline related compound A3 | 0.8 | NMT 0.3 |
Cabergoline | 1.0 | |
Cabergoline related compound C4 | 2.9 | NMT 0.3 |
Any unspecified impurity | | NMT 0.10 |
Total | | NMT 0.8 |
1
(6aR,9R,10aR)-N-[3-(Dimethylamino)propyl]-7-(prop-2-enyl)-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinoline-9-carboxamide.
2
(6aR,9R,10aR)-N9-[3-(Dimethylamino)propyl]-N4-ethyl-7-(prop-2-enyl)-6a,7,8,9,10,10a-hexahydroindolo[4,3-fg]quinoline-4,9(6H)-dicarboxamide.
3
(6aR,9R,10aR)-7-(Prop-2-enyl)-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinoline-9-carboxylic acid.
4
(6aR,9R,10aR)-N9-[3-(Dimethylamino)propyl]-N4-ethyl-N9-(ethylcarbamoyl)-7-(prop-2-enyl)-6a,7,8,9,10,10a-hexahydroindolo[4,3-fg]quinoline-4,9(6H)-dicarboxamide.
|
Topic/Question | Contact | Expert Committee |
Monograph | Ravi Ravichandran, Ph.D.
Senior Scientist 1-301-816-8330 |
(MDPP05) Monograph Development-Psychiatrics and Psychoactives |
Reference Standards | Lili Wang, Technical Services Scientist 1-301-816-8129 RSTech@usp.org |